Showing results (241-250 of 253) with videos related to

Sort By:
Pageof 26
American Journal of Nephrology|March 8, 2013
Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON)Dick de Zeeuw, Tadao Akizawa, Rajiv Agarwal, et al.
Diabetes, Obesity & Metabolism|January 24, 2019
Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney diseaseDavid M Charytan, Scott D Solomon, Peter Ivanovich, et al.
The New England Journal of Medicine|November 12, 2013
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney diseaseDick de Zeeuw, Tadao Akizawa, Paul Audhya, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|June 9, 2009
Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)Marc A Pfeffer, Emmanuel A Burdmann, Chao-Yin Chen, et al.
Diabetes, Obesity & Metabolism|October 13, 2021
Comparison of treatment with insulin degludec and glargine U100 in patients with type 1 diabetes prone to nocturnal severe hypoglycaemia: The HypoDeg randomized, controlled, open-label, crossover trialUlrik Pedersen-Bjergaard, Rikke M Agesen, Julie M B Brøsen, et al.
The New England Journal of Medicine|November 3, 2009
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney diseaseMarc A Pfeffer, Emmanuel A Burdmann, Chao-Yin Chen, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 23, 2018
Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)Finnian R Mc Causland, Brian Claggett, Emmanuel A Burdmann, et al.
American Heart Journal|May 3, 2005
Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney diseaseT-Christian H Mix, Robert M Brenner, Mark E Cooper, et al.
Diabetes|July 18, 2008
G/T substitution in intron 1 of the UNC13B gene is associated with increased risk of nephropathy in patients with type 1 diabetesDavid-Alexandre Trégouet, Per-Henrik Groop, Steven McGinn, et al.
The New England Journal of Medicine|April 1, 2009
Rosuvastatin and cardiovascular events in patients undergoing hemodialysisBengt C Fellström, Alan G Jardine, Roland E Schmieder, et al.
Pageof 26